Autopsy report · NCT01564277
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Cause of deathSlow enrollment
“low accrual”
Life of this trial
- Registered 5 months after it had already started.
- Ran for about 4 years 8 months before it stopped.
- 24 participants enrolled.
- Results were posted on the registry 1 year 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Roswell Park Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- rasburicase; allopurinol
- Participants
- 24
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.